RETA

Reata Pharmaceuticals, Inc. Class A Common Stock
RETA

Overview Fund Activity
Delisted

RETA was delisted on the 25th of September, 2023.

Back to rankings

149 hedge funds and large institutions have $884M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 40 increasing their positions, 50 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
149
Holders Change
-2
Holders Change %
-1.32%
% of All Funds
2.36%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
34
Increased
40
Reduced
50
Closed
34
Calls
$21.3M
Puts
$70.1M
Net Calls
-$48.8M
Net Calls Change
-$54M

Top Buyers

1
EC
EcoR1 Capital
California
$64.7M
2
CCM
Camber Capital Management
Massachusetts
$49.1M
3
BC
Boxer Capital
California
$40.6M
4
SI
Sofinnova Investments
California
$19.7M
5
Fidelity Investments
Fidelity Investments
Massachusetts
$13.6M

Top Sellers

1
Invesco
Invesco
Georgia
$1.84M
2
Goldman Sachs
Goldman Sachs
New York
$3.52M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
$18.4M
4
Millennium Management
Millennium Management
New York
$7.82M
5
DFO
Duquesne Family Office
New York
$1.93M
Name Holding Trade Value Shares
Change 		Shares
Change %
DFCM
176
Dark Forest Capital Management
Puerto Rico
– -$5K -206 Closed
AF
177
Allworth Financial
California
– -$3K -109 Closed
4 5 6 7
8